ScreenPoint Medical

Breast cancer is the most commonly diagnosed cancer in women worldwide, and early detection is the single factor with the greatest impact on survival outcomes. Yet mammography screening programs face a hard reality: reading mammograms is a cognitively demanding task, subject to fatigue and variability between radiologists. Cancers can be missed, or findings can be flagged that turn out to be benign — generating unnecessary anxiety and biopsies. ScreenPoint Medical, a Dutch startup based in Nijmegen, developed Transpara to address precisely this challenge. Transpara is an AI platform designed to support mammogram reading, compatible with both standard 2D images and digital breast tomosynthesis (3D). The system analyzes each image, assigns a risk score, highlights suspicious areas, and provides the radiologist with an automated second layer of assessment. The goal is not to replace the physician but to make them more accurate and more efficient — reducing false negatives, the cancers that get missed, without increasing unnecessary recalls. ScreenPoint's approach stands out for the depth of its clinical validation. Transpara has been studied on large cohorts of real patients within European screening programs, and published clinical data shows measurable improvements in diagnostic performance compared to reading without AI support. This level of scientific evidence is critical in a field where clinician trust must be earned with data, not marketing. The addressable market is substantial: national mammography screening programs involve millions of women every year across Europe, and the ongoing shortage of experienced radiologists makes AI a structural ally rather than a technological novelty. The business model targets hospitals, radiology centers, and national screening networks. ScreenPoint Medical represents one of the most compelling cases of AI applied to diagnostics: not a laboratory algorithm, but a clinically validated tool that performs in real-world practice.